Defendant Mix-Up Ends Biotech FCA Suit, For Now - Law360
COVID-19 billing and other alleged schemes to defraud Medicare to the biotech company it named as a defendant, dismissing the complaint with leave to amend. . . . Law360 is on it, so you are, too. ...